
CLAIMS

1. Use of a compound of following general formula (I):



(I)

or a pharmaceutically acceptable salt and/or solvate thereof, wherein:


- Het is a nitrogen-containing heterocycloalkyl;
- X is a single bond, a (C_1-C_6)alkyl group or a (C_1-C_6)alkoxy group, in particular a single bond, a (C_1-C_3)alkyl group or a (C_1-C_3)alkoxy group;
- Y is a group selected from $–R_{10}C(O)NHR_{11}$; (C_1-C_6)alkyl; or (C_1-C_6)alkyl-aryl with (C_1-C_6)alkyl optionally substituted with =O, =S or a phenyl and with aryl optionally substituted with one or several substituents selected from hydrogen atom, halo,-CN, $-NO_2$, $-OR_{12}$, $-NR_{13}R_{14}$, $-C(O)OR_{15}$, $-C(O)NR_{16}R_{17}$, $-S(O)_2NR_{18}R_{19}$, $-S(O)_2R_{20}$, $-NHS(O)_2R_{21}$, $-NHC(O)R_{22}$, or a group selected from (C_1-C_6)alkyl, aryl, (C_1-C_6)alkyl-aryl, heterocycle, (C_1-C_6)alkyl-heterocycle, said group being optionally substituted with one or several groups selected from halo, (C_1-C_6)alkyl, $-OR_{23}$ or $-OC(O)R_{24}$, or with two adjacent substituents which form together with the carbon atoms to which they are chemically linked an heterocycle;
- R_1 to R_4 are, independently of one another, hydrogen atom or a group selected from halo, $-NO_2$, –CN, $-OR_{25}$, $-NR_{26}R_{27}$, $-C(O)OR_{28}$, $-S(O)_2R_{29}$, or a (C_1-C_6)alkyl group optionally substituted with one or several groups selected from halo or $–OR_{30}$;
- R_{10} to R_{30} are, independently of one another, hydrogen atom, halo, or a group selected from (C_1-C_6)alkyl, aryl, (C_1-C_6)alkyl-aryl, heterocycle, (C_1-C_6)alkyl-heterocycle, said group being optionally substituted with one or several groups selected from halo, (C_1-C_6)alkyl, CF_3 or $–OR_{31;}$

- R_{31} is hydrogen atom, halo or a (C_1-C_6)alkyl group;

in the manufacture of a medicament for the prevention and/or the treatment of acne.

2. The use according to claim 1, wherein Y is (C_1-C_6)alkyl-phenyl with phenyl optionally substituted with one or several substituents, preferably one to four substituents, notably one or two substituents, selected from hydrogen atom, halo,-CN, -NO_2, -OR_{12}, -$NR_{13}R_{14}$, -$C(O)NR_{16}R_{17}$, -$S(O)_2NR_{18}R_{19}$, or a group selected from (C_1-C_6)alkyl, aryl, (C_1-C_6)alkyl-aryl, heterocycle or (C_1-C_6)alkyl-heterocycle.

3. The use according to claim 1 or 2, wherein said compound is of the following general formula (Ia):




(Ia)

or a pharmaceutically acceptable salt and/or solvate thereof, wherein:

- Het is a nitrogen-containing heterocycloalkyl;
- R_1 to R_4 are as defined in claim 1; and
- R_5 to R_9 are, independently of one another, hydrogen atom, halo,-CN, -NO_2, -OR_{12}, -$NR_{13}R_{14}$, -$C(O)OR_{15}$, -$C(O)NR_{16}R_{17}$, -$S(O)_2NR_{18}R_{19}$, -$S(O)_2R_{20}$, -$NHS(O)_2R_{21}$, -$NHC(O)R_{22}$, or a group selected from (C_1-C_6)alkyl, aryl, (C_1-C_6)alkyl-aryl, heterocycle, (C_1-C_6)alkyl-heterocycle, said group being optionally substituted with one or several groups selected from halo, (C_1-C_6)alkyl, -OR_{23} or -$OC(O)R_{24}$; or the couple R_5-R_6, R_6-R_7, R_8-R_8 or R_8-R_9 form together with the carbon atoms to which they are chemically linked, an heterocycle, while the others are hydrogen atoms; R_{12} ro R_{24} being as defined in claim 1.

4. The use according to any one of claims 1 to 3, wherein Het is a piperazinyl or a piperidinyl.

5. The use according to any one of claims 1 to 4, wherein said compound is of the following general formula (Ib):



(Ib),


or a pharmaceutically acceptable salt and/or solvate thereof, R_1 to R_9 being as defined in claim 1.

6. The use according to any one of claims 1 to 5, wherein R_1 to R_4 are, independently of one another, hydrogen atom or a group selected from halo, $-NO_2$, –CN, $-OR_{25}$, $-NR_{26}R_{27}$ or a (C_1-C_6)alkyl group, in particular R_1 to R_4 are, independently of one another, hydrogen atom or a group selected from halo, $-OR_{25}$, $-NR_{26}R_{27}$ or a (C_1-C_6)alkyl group, more particularly R_1 to R_4 are, independently of one another, hydrogen atom or halo; R_{25} to R_{27} being as defined in claim 1.

7. The use according to any one of claims 3 to 6, wherein R_5 to R_9 are, independently of one another, hydrogen atom, halo, -CN, $-NO_2$, $-OR_{12}$, $-NR_{13}R_{14}$, $-C(O)NR_{16}R_{17}$, $-S(O)_2NR_{18}R_{19}$, or a group selected from (C_1-C_6)alkyl, aryl, (C_1-C_6)alkyl-aryl, heterocycle or (C_1-C_6)alkyl-heterocycle; preferably R_5 to R_9 are, independently of one another, hydrogen atom, halo,-CN, $-NO_2$, $-OR_{12}$, $-NR_{13}R_{14}$, $-C(O)NR_{16}R_{17}$, $-S(O)_2NR_{18}R_{19}$, or a group selected from (C_1-C_6)alkyl, heterocycle or (C_1-C_6)alkyl-heterocycle; more particularly R_5 to R_9 are, independently of one another, hydrogen atom, halo, $-OR_{12}$, $-NR_{13}R_{14}$ or a (C_1-C_6)alkyl group; R_{12} to R_{19} being as defined in claim 1.

8. The use according to any one of claims 1 to 7, wherein R_{10} to R_{30} are, independently of one another, hydrogen atom, halo, or a group selected from (C_1-C_6)alkyl.

9. The use according to any one of claims 1 to 8, wherein said compound is of the following formula (Ic):



(Ic),

or a pharmaceutically acceptable salt and/or solvate thereof, preferably it is the dihydrochloride salt of compound (Ic).

10. A pharmaceutical composition comprising at least one compound according to any one of claims 1 to 9 and at least one pharmaceutically acceptable excipient, in the manufacture of a medicament, for the prevention and/or the treatment of acned.

11. The pharmaceutical composition for use according to claim 10, wherein it further comprises another active principle, such as topical antibiotic (erythromycine, dalacine), topical anti-inflammatory (benzoyl peroxydes derivatives), topical anti-seborrheic (isotretinoin, tretinoin, adapalene), zinc derivatives (zinc gluconate), cyclins, or isotretinoin.